Right ventricular stroke work index in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A retrospective observational study

The right ventricular stroke work index (RVSWI) reflects the active work of the right ventricle (RV), but its clinical usefulness is not yet fully known in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to evaluate the correlation of RVSWI to clinical parameters, the presence of comorbidities and response to therapy. We performed a retrospective observational study of 54 patients (PAH: <i>N</i> = 30, CTEPH: <i>N</i> = 24) and control patients (<i>N</i> = 11), and collected clinical data including RVSWI and comorbidities at baseline. We also compared changes in the parameters of the four-strata mortality risk score at follow-up (median time of 12 months) after the initiation of therapy between patients with low- (<1450 mmHg*mL/m<sup>2</sup>, <i>N</i> = 18) and high-RVSWI values (≥1450 mmHg*mL/m<sup>2</sup>, <i>N</i> = 19). RVSWI at diagnosis was higher in PAH/CTEPH compared to control subjects (1408 ± 391 vs. 704 ± 140 mmHg*mL/m<sup>2</sup>, <i>p</i> < 0.001, mean ± standard deviation, <i>t</i>-test), but did not differ between PAH and CTEPH patients (1406 ± 342 vs. 1409 ± 470 mmHg*mL/m<sup>2</sup>, <i>p</i> = 0.98). Patients without comorbidities had higher RVSWI than those with comorbidities (<i>N</i> = 23: 1522 ± 400 vs. <i>N</i> = 31: 1323 ± 384 mmHg*mL/m<sup>2</sup>, <i>p</i> = 0.04), which was also found in PAH (<i>p</i> < 0.001), but not in CTEPH (<i>p</i> = 0.37). A greater improvement in the four-strata mortality risk score (<i>p</i> < 0.05) and a trend for a larger reduction in N-terminal proB-type natriuretic peptide concentration (<i>p</i> = 0.06) were observed in the high-RVSWI subgroup than in the low-RVSWI patients at follow-up. In PAH and CTEPH, RVSWI provides additional information on RV function in comorbidities, and it may predict response to specific therapy. Regular monitoring of RVSWI may aid in optimizing therapy selection and timing.

Authors

Institutions

Publication Details

Journal
Pulmonary Circulation
Published
2024-10-01
DOI
https://doi.org/10.1002/pul2.12433
Citations
2
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Right ventricular stroke work index in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A retrospective observational study

Zsófia Lázár, Luca Valkó, Györgyi Csósza, Elek Dinya et al.
2 citations
Pulmonary Circulation
Pulmonary Hypertension Research and Treatments
0.84
article

Right ventricular stroke work index in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A retrospective observational study

Zsófia Lázár, Luca Valkó, Györgyi Csósza, Elek Dinya, György Losonczy, Kristóf Karlócai, Veronika Müller
article en
2 citations

Abstract

The right ventricular stroke work index (RVSWI) reflects the active work of the right ventricle (RV), but its clinical usefulness is not yet fully known in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to evaluate the correlation of RVSWI to clinical parameters, the presence of comorbidities and response to therapy. We performed a retrospective observational study of 54 patients (PAH: <i>N</i> = 30, CTEPH: <i>N</i> = 24) and control patients (<i>N</i> = 11), and collected clinical data including RVSWI and comorbidities at baseline. We also compared changes in the parameters of the four-strata mortality risk score at follow-up (median time of 12 months) after the initiation of therapy between patients with low- (<1450 mmHg*mL/m<sup>2</sup>, <i>N</i> = 18) and high-RVSWI values (≥1450 mmHg*mL/m<sup>2</sup>, <i>N</i> = 19). RVSWI at diagnosis was higher in PAH/CTEPH compared to control subjects (1408 ± 391 vs. 704 ± 140 mmHg*mL/m<sup>2</sup>, <i>p</i> < 0.001, mean ± standard deviation, <i>t</i>-test), but did not differ between PAH and CTEPH patients (1406 ± 342 vs. 1409 ± 470 mmHg*mL/m<sup>2</sup>, <i>p</i> = 0.98). Patients without comorbidities had higher RVSWI than those with comorbidities (<i>N</i> = 23: 1522 ± 400 vs. <i>N</i> = 31: 1323 ± 384 mmHg*mL/m<sup>2</sup>, <i>p</i> = 0.04), which was also found in PAH (<i>p</i> < 0.001), but not in CTEPH (<i>p</i> = 0.37). A greater improvement in the four-strata mortality risk score (<i>p</i> < 0.05) and a trend for a larger reduction in N-terminal proB-type natriuretic peptide concentration (<i>p</i> = 0.06) were observed in the high-RVSWI subgroup than in the low-RVSWI patients at follow-up. In PAH and CTEPH, RVSWI provides additional information on RV function in comorbidities, and it may predict response to specific therapy. Regular monitoring of RVSWI may aid in optimizing therapy selection and timing.

Pulmonary CirculationVol. 14(4)
Semmelweis University (HU)
Good health and well-being
Openalex Percentile: Top 22%
Pulmonary Hypertension Research and Treatments
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.